Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
JNJ 
Johnson & Johnson (JNJ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: JNJ (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
24 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $169.18
1 Year Target Price $169.18
| 7 | Strong Buy |
| 4 | Buy |
| 13 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.84% | Avg. Invested days 39 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 379.41B USD | Price to earnings Ratio 17.55 | 1Y Target Price 169.18 |
Price to earnings Ratio 17.55 | 1Y Target Price 169.18 | ||
Volume (30-day avg) 24 | Beta 0.41 | 52 Weeks Range 138.38 - 168.55 | Updated Date 07/11/2025 |
52 Weeks Range 138.38 - 168.55 | Updated Date 07/11/2025 | ||
Dividends yield (FY) 3.40% | Basic EPS (TTM) 8.94 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-16 | When Before Market | Estimate 2.68 | Actual - |
Profitability
Profit Margin 24.42% | Operating Margin (TTM) 29.41% |
Management Effectiveness
Return on Assets (TTM) 7.77% | Return on Equity (TTM) 29.45% |
Valuation
Trailing PE 17.55 | Forward PE 14.84 | Enterprise Value 390983897475 | Price to Sales(TTM) 4.25 |
Enterprise Value 390983897475 | Price to Sales(TTM) 4.25 | ||
Enterprise Value to Revenue 4.38 | Enterprise Value to EBITDA 11.27 | Shares Outstanding 2406070016 | Shares Floating 2402416048 |
Shares Outstanding 2406070016 | Shares Floating 2402416048 | ||
Percent Insiders 0.06 | Percent Institutions 74.05 |
Upturn AI SWOT
Johnson & Johnson
Company Overview
History and Background
Johnson & Johnson was founded in 1886 by Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson. Initially focused on sterile surgical dressings, the company expanded into consumer health, pharmaceuticals, and medical devices. Key milestones include going public in 1944 and numerous acquisitions expanding its product portfolio.
Core Business Areas
- Innovative Medicine: Develops and markets pharmaceuticals in therapeutic areas such as immunology, oncology, neuroscience, cardiovascular, and infectious diseases.
- MedTech: Offers a broad portfolio of medical devices used in orthopedics, surgery, interventional solutions, and vision care.
Leadership and Structure
The CEO is Joaquin Duato. J&J operates with a decentralized structure, with each business segment having significant autonomy.
Top Products and Market Share
Key Offerings
- Stelara: A biologic therapy used to treat autoimmune diseases like psoriasis and Crohn's disease. Competitors: AbbVie's Humira, Amgen's Enbrel. Stelara is one of JNJ's best performing medications. Revenue of $9.7 billion in 2022.
- Invega Sustenna/Xeplion: An injectable antipsychotic medication used to treat schizophrenia. Competitors: AstraZeneca's Seroquel, Otsuka's Abilify. Sales around $4.0 billion in 2022.
- Acuvue Contact Lenses: A leading brand of disposable contact lenses. Competitors: Alcon's Dailies, CooperVision's Biofinity. Acuvue is one of JNJ's leading contact lens brands holding about 35% of the market share.
Market Dynamics
Industry Overview
The healthcare industry is experiencing growth driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. High regulatory barriers and intense competition characterize the market.
Positioning
Johnson & Johnson is a diversified healthcare company with a strong global presence. Its competitive advantages include a diverse product portfolio, strong brand reputation, and significant R&D investment.
Total Addressable Market (TAM)
The global healthcare market is estimated at over $10 trillion. J&J is positioned to capture a significant share due to its diversified portfolio and global reach.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Strong brand reputation
- Significant R&D investment
- Global presence
- Financial stability
Weaknesses
- Exposure to litigation risks
- Dependence on key products
- Slow organic growth
- Complex organizational structure
Opportunities
- Expanding into emerging markets
- Developing innovative products
- Acquiring complementary businesses
- Leveraging digital technologies
- Growth in biosimilars
Threats
- Increasing competition
- Patent expirations
- Regulatory changes
- Economic downturns
- Product recalls
Competitors and Market Share
Key Competitors
- PFE
- MRK
- ABBV
- NVO
Competitive Landscape
Johnson & Johnson benefits from diversification but faces intense competition across all its business segments. Its brand reputation and R&D capabilities are key advantages. A disadvantage lies in being very large and slower to adopt new tech.
Major Acquisitions
Abiomed
- Year: 2022
- Acquisition Price (USD millions): 16600
- Strategic Rationale: Strengthen J&J's MedTech portfolio in cardiovascular segment and offer opportunities for growth in heart recovery.
Growth Trajectory and Initiatives
Historical Growth: J&J's historical growth has been driven by acquisitions and new product launches. However, organic growth has been relatively slow in recent years.
Future Projections: Analysts project moderate revenue growth in the coming years, driven by new products and expansion into emerging markets.
Recent Initiatives: Recent initiatives include focusing on core pharmaceutical and medtech businesses, spinning off consumer health division (Kenvue), and investing in digital health technologies.
Summary
Johnson & Johnson is a financially stable and diversified healthcare giant with a strong brand and global reach. The recent spin-off will let it focus more on the Innovative Medicine and MedTech segments. The company benefits from its high R&D investments and is well-positioned to capitalize on growing healthcare needs but needs to focus on faster organic growth and manage litigation risks. Despite strong financial performance, slower organic growth and heavy reliance on a few key products are areas to watch.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Johnson & Johnson's SEC filings
- Analyst reports
- Industry publications
- Company website
- Third party market data.
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Past performance is not indicative of future results. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Johnson & Johnson
Exchange NYSE | Headquaters New Brunswick, NJ, United States | ||
IPO Launch date 1944-09-24 | CEO & Chairman Mr. Joaquin Duato | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 138100 | Website https://www.jnj.com |
Full time employees 138100 | Website https://www.jnj.com | ||
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.